All News

Every day seems to link another food or behavior to my cancer diagnosis. Those endless recommendations sometimes just minimize what I am going through. Am I wrong to say enough is enough?

The NCCN recently designated Optune, which has been shown to slow and reverse tumor growth, a category 2A recommendation for some patients with GBM.

CURE spoke with the founder of CORAL 65 on the unique issues older patients with cancer face.

Many people may not know about mastocytosis, but thanks to a new online initiative, patients and researchers are gaining a better understanding of the disorder.

The state of the world is a major buzzkill right now...

Tweet chats are no longer just a social way to share ideas. Now, cancer innovators have the opportunity to win grants that will help them develop their ideas on how to improve care.

With a number of FDA approvals, immunotherapy is becoming a key player in the treatment of lung cancer. CURE spoke with Mark W. Kris to see what's next.

Ruben Mesa discusses Jakafi's potential in treating myelofibrosis.

If you've relapsed after you thought you'd been cured, you know what a shock it is. Relapsing twice, after two transplants, turns out to have a surprisingly different effect on Kevin.

Two phase 3 trials led to Darzalex being granted a breakthrough therapy designation by the FDA.

Two trials testing Gilotrif's efficacy in head and neck cancer were stopped after a panel decided it was unlikely the drug would prove beneficial.

The treatment landscape for triple-negative breast cancer is shifting as findings from trials continue to be explored.

Losing breasts is often difficult for women to accept.

Is there a possible connection between chemo and AFIB?

As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving.

A phase 3 study proved that Tagrisso can benefit some patients with NSCLC.

Neratinib reduced recurrence or death for some women with breast cancer, according to five-year data from a phase 3 trial.

Cancer is a great teacher of many valuable lessons.

Cancer is temporary, but family is forever.

Olga Ivanov talks with CURE about the multiple side effects, including changes in sex drive, that happen after women have risk-reducing surgery.

Another biosimilar for Herceptin proved to have similar outcomes as the original drug for patients with breast cancer in a phase 3 trial.

A new online tool can help patients with prostate cancer determine if active surveillance is the right decision.

Musings on mortality

A lesson in the power of graciousness for the hardheaded cancer patient.

Overwhelming evidence shows that particle pollution in the outdoor air we breathe — like that coming from vehicle exhaust, coal-fired power plants and other industrial sources — can cause lung cancer.

There’s been some debate in recent years about the true value and effectiveness of certain types of cancer screenings. This is, of course, a perfectly reasonable thing to be doing both in the name of advancing medical science, and especially in an environment where there's so much downward pressure on the costs of healthcare.

Because of a nation-wide shortage of oncologists, nurses and nurse practitioners are becoming the key leaders in survivorship care.

CURE spoke with Akash Patnaik about immunotherapy's role in prostate cancer.